Men currently being treated with Xofigo should ask their doctors, today, “What should I do in light of the current shortage of Xofigo?” In our October 8, 2014 bog post, we cited data from the ALSYMPCA clinical trial for Xofigo, which was given to Malecare during an interview with Joseph Germino, MD, PhD, Vice President [...]
The world wide supply of Xofigo (radium Ra-223 dichloride) available for patients will run out on October 10, 2014. Xofigo is the newly FDA approved treatment for men with castrate resistant metastatic prostate cancer (CRPC) with bone metastases without any known visceral metastases. Individual batches of drugs are inspected prior to release to patients. Bayer’s [...]
Oligometastasis can be described as a state of limited metastatic disease following failed primary treatment or even prostate cancer as it is first diagnosed. Many doctors believe that it is amenable to aggressive local therapy to achieve long-term survival. In a review designed to explore the role of ablative radiotherapy and surgical management of oligo-metastatic [...]
A man in the advanced prostate cancer online support group has asked, “Why the radiation (external beam to relieve bone pain from prostate cancer and to protect the bones from fractures) is given in so many "mini" doses rather than one or two larger doses. The answer is it doesn't necessarily have to be delivered [...]
Randy Sheffield, a member of the Malecare Advanced Prostate Cancer Online support group recently has had his fight with advanced prostate cancer made even more complex when he developed Osteonecrosis of the jaw (ONJ). ONJ is an uncommon but terrible side effect of taking bisphosphonates. Randy wrote a warning to all the members of the [...]
Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]
It is important that survivors keep up on the professional standards of our doctors to make sure that we receive the best care and the most current care. It is easy for doctors to just do it the way they were first trained, even if their training was twentyor thirty years ago. Recent news includes [...]
As prostate cancer progresses so does the pain we will suffer. In the normal course we will also progress on to different drugs to help control the pain. Opioids are one of the most common of these drugs prescribed to help control pain. As with all drugs opioids have many side effects. One of the [...]
Provenge or Sipuleucel-T (sip-T) remains not well understood by many prostate cancer survivors as well as some treating physicians. Because Provenge does not immediately control PSA or disease progression it creates a situation where some individuals are skeptical as to its efficacy. This is true despite the clear survival advantage demonstrated in clinical trials. This [...]
It is generally believed that combination hormone therapy (ADT 2, 3 or 4) is superior to mono-therapy (with just one drug). With this in mind researchers investigated the survival of hormone-naïve prostate cancer survivors diagnosed with prostate-specific antigen (PSA) over 500 ng/ml. They extracted data of prostate cancer survivors from the Japan Study Group of [...]
